Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Mouse model of mevalonate kinase deficiency: comparison of cytokine and chemokine profile with that of human patients.

Marcuzzi A, Zanin V, Kleiner G, Monasta L, Crovella S.

Pediatr Res. 2013 Sep;74(3):266-71. doi: 10.1038/pr.2013.96.

PMID:
23760140
2.

Natural isoprenoids inhibit LPS-induced-production of cytokines and nitric oxide in aminobisphosphonate-treated monocytes.

Marcuzzi A, Tommasini A, Crovella S, Pontillo A.

Int Immunopharmacol. 2010 Jun;10(6):639-42. doi: 10.1016/j.intimp.2010.03.008.

PMID:
20304105
3.

Specific increase in caspase-1 activity and secretion of IL-1 family cytokines: a putative link between mevalonate kinase deficiency and inflammation.

Normand S, Massonnet B, Delwail A, Favot L, Cuisset L, Grateau G, Morel F, Silvain C, Lecron JC.

Eur Cytokine Netw. 2009 Sep;20(3):101-7. doi: 10.1684/ecn.2009.0163. Review.

4.

Natural isoprenoids are able to reduce inflammation in a mouse model of mevalonate kinase deficiency.

Marcuzzi A, Pontillo A, De Leo L, Tommasini A, Decorti G, Not T, Ventura A.

Pediatr Res. 2008 Aug;64(2):177-82. doi: 10.1203/PDR.0b013e3181761870.

PMID:
18391837
5.

Geraniol rescues inflammation in cellular and animal models of mevalonate kinase deficiency.

Marcuzzi A, Crovella S, Pontillo A.

In Vivo. 2011 Jan-Feb;25(1):87-92.

PMID:
21282739
6.

Targeting farnesyl-transferase as a novel therapeutic strategy for mevalonate kinase deficiency: in vitro and in vivo approaches.

De Leo L, Marcuzzi A, Decorti G, Tommasini A, Crovella S, Pontillo A.

Pharmacol Res. 2010 Jun;61(6):506-10. doi: 10.1016/j.phrs.2010.02.012.

PMID:
20206266
7.

Decreased cholesterol levels reflect a consumption of anti-inflammatory isoprenoids associated with an impaired control of inflammation in a mouse model of mevalonate kinase deficiency.

Marcuzzi A, Decorti G, Pontillo A, Ventura A, Tommasini A.

Inflamm Res. 2010 May;59(5):335-8. doi: 10.1007/s00011-010-0168-6.

PMID:
20174853
8.

The farnesyltransferase inhibitors tipifarnib and lonafarnib inhibit cytokines secretion in a cellular model of mevalonate kinase deficiency.

Marcuzzi A, De Leo L, Decorti G, Crovella S, Tommasini A, Pontillo A.

Pediatr Res. 2011 Jul;70(1):78-82. doi: 10.1038/pr.2011.303.

PMID:
21430599
9.

Systemic and neuronal inflammatory markers in a mouse model of mevalonate kinase deficiency: a strain-comparative study.

Kleiner G, Celsi F, Tricarico PM, Zacchigna S, Crovella S, Marcuzzi A.

In Vivo. 2013 Nov-Dec;27(6):715-22.

PMID:
24292573
10.

Temperature and drug treatments in mevalonate kinase deficiency: an ex vivo study.

Tricarico PM, Kleiner G, Piscianz E, Zanin V, Monasta L, Crovella S, Marcuzzi A.

Biomed Res Int. 2013;2013:715465. doi: 10.1155/2013/715465.

11.

Hyper-IgD syndrome or mevalonate kinase deficiency.

Stoffels M, Simon A.

Curr Opin Rheumatol. 2011 Sep;23(5):419-23. doi: 10.1097/BOR.0b013e328349c3b1. Review.

PMID:
21760510
12.

Current advances in the understanding and treatment of mevalonate kinase deficiency.

Esposito S, Ascolese B, Senatore L, Bosis S, Verrecchia E, Cantarini L, Rigante D.

Int J Immunopathol Pharmacol. 2014 Oct-Dec;27(4):491-8. Review.

PMID:
25572728
13.

Block of the mevalonate pathway triggers oxidative and inflammatory molecular mechanisms modulated by exogenous isoprenoid compounds.

Tricarico PM, Kleiner G, Valencic E, Campisciano G, Girardelli M, Crovella S, Knowles A, Marcuzzi A.

Int J Mol Sci. 2014 Apr 22;15(4):6843-56. doi: 10.3390/ijms15046843.

14.

HMG-CoA reductase inhibition induces IL-1beta release through Rac1/PI3K/PKB-dependent caspase-1 activation.

Kuijk LM, Beekman JM, Koster J, Waterham HR, Frenkel J, Coffer PJ.

Blood. 2008 Nov 1;112(9):3563-73. doi: 10.1182/blood-2008-03-144667.

15.

A role for geranylgeranylation in interleukin-1beta secretion.

Mandey SH, Kuijk LM, Frenkel J, Waterham HR.

Arthritis Rheum. 2006 Nov;54(11):3690-5.

17.
18.

Regulatory adaptation of isoprenoid biosynthesis and the LDL receptor pathway in fibroblasts from patients with mevalonate kinase deficiency.

Hoffmann GF, Wiesmann UN, Brendel S, Keller RK, Gibson KM.

Pediatr Res. 1997 Apr;41(4 Pt 1):541-6.

PMID:
9098857
19.
20.

The effect of clodronate on a mevalonate kinase deficiency cellular model.

Zanin V, Marcuzzi A, Piscianz E, Vuch J, Bianco AM, Monasta L, Decorti G, Crovella S.

Inflamm Res. 2012 Dec;61(12):1363-7. doi: 10.1007/s00011-012-0537-4.

PMID:
22851203
Items per page

Supplemental Content

Support Center